{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:10Z","timestamp":1790936350835,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["016.176.640"],"award-info":[{"award-number":["016.176.640"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09150182010020"],"award-info":[{"award-number":["09150182010020"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008359","name":"Digestive Diseases Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016060","name":"Stichting De Cock-Hadders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gastha.2025.100745","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T23:03:50Z","timestamp":1752620630000},"page":"100745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beta-Klotho Protein Expression in Healthy Human Tissues and Liver Biopsies From Patients With MASLD or MASH"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-7916","authenticated-orcid":false,"given":"Alexandra S.","family":"Aaldijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicky","family":"Struik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristy R.C.","family":"Verzijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Nieuwdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"Eilers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina C.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan G.","family":"Holleboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gastha.2025.100745_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2025.100745_bib2","first-page":"2287","article-title":"Precision medicine and nucleotide-based therapeutics to treat MASH","volume":"31","author":"Caddeo","year":"2024","journal-title":"Clin Mol Hepatolo"},{"issue":"12","key":"10.1016\/j.gastha.2025.100745_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/apt.17995","article-title":"Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: a multicenter study in Japan","volume":"59","author":"Tsutsumi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2025.100745_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.gastha.2025.100745_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/apt.17889","article-title":"Meta-analysis: efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis","volume":"59","author":"Lin","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gastha.2025.100745_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102357","article-title":"Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Marey","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastha.2025.100745_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fendo.2015.00193","article-title":"Fibroblast growth factor signaling in metabolic regulation","volume":"6","author":"Nies","year":"2016","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.gastha.2025.100745_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/ajpendo.00156.2024","article-title":"The role of FGF19 in metabolic regulation: insights from preclinical models to clinical trials","volume":"327","author":"Carvalho","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.gastha.2025.100745_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"10.1016\/j.gastha.2025.100745_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application","volume":"30","author":"Struik","year":"2019","journal-title":"Curr Opinion Lipidol"},{"issue":"10","key":"10.1016\/j.gastha.2025.100745_bib11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.gastha.2025.100745_bib12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2337\/db18-1305","article-title":"FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis","volume":"68","author":"De Paoli","year":"2019","journal-title":"Diabetes"},{"issue":"10126","key":"10.1016\/j.gastha.2025.100745_bib13","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"291","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gastha.2025.100745_bib14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gastha.2025.100745_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"10165","key":"10.1016\/j.gastha.2025.100745_bib16","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"293","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gastha.2025.100745_bib17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatology"},{"issue":"7","key":"10.1016\/j.gastha.2025.100745_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Etruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.gastha.2025.100745_bib19","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/biomedicines12102328","article-title":"Comparative analysis of resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials","volume":"12","author":"Ayesh","year":"2024","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.gastha.2025.100745_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.gastha.2025.100745_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab"},{"issue":"1\u20132","key":"10.1016\/j.gastha.2025.100745_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0925-4773(00)00439-1","article-title":"Molecular cloning and expression analyses of mouse \u03b2klotho, which encodes a novel Klotho family protein","volume":"98","author":"Ito","year":"2000","journal-title":"Mech Dev"},{"issue":"6655","key":"10.1016\/j.gastha.2025.100745_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.gastha.2025.100745_bib24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI23076","article-title":"Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho","volume":"115","author":"Ito","year":"2005","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.gastha.2025.100745_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1152\/ajpendo.00182.2018","article-title":"\u03b2-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice","volume":"315","author":"Somm","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.gastha.2025.100745_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"issue":"20","key":"10.1016\/j.gastha.2025.100745_bib27","doi-asserted-by":"crossref","first-page":"15482","DOI":"10.1074\/jbc.275.20.15482","article-title":"Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4","volume":"275","author":"Yu","year":"2000","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.gastha.2025.100745_bib28","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"\u03b2Klotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.gastha.2025.100745_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.2007-0313","article-title":"\u03b2Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c","volume":"22","author":"Suzuki","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"3","key":"10.1016\/j.gastha.2025.100745_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2019.10.011","article-title":"\u03b2-Klotho gene variation is associated with liver damage in children with NAFLD","volume":"72","author":"Dongiovanni","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastha.2025.100745_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103249","article-title":"The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation","volume":"65","author":"Panera","year":"2021","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.gastha.2025.100745_bib32","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/jmri.27703","article-title":"Assessment of imaging Modalities against liver biopsy in nonalcoholic fatty liver disease: the Amsterdam NAFLD-NASH cohort","volume":"54","author":"Troelstra","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.gastha.2025.100745_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gastha.2025.100745_bib34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2025.100745_bib37","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1038\/s41467-018-06642-y","article-title":"Enhanced validation of antibodies for research applications","volume":"9","author":"Edfors","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2025.100745_bib38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nmeth.3995","article-title":"A proposal for validation of antibodies","volume":"13","author":"Uhlen","year":"2016","journal-title":"Nat Methods"},{"issue":"31","key":"10.1016\/j.gastha.2025.100745_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2169","article-title":"A single\u2013cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.gastha.2025.100745_bib40","article-title":"Tissue-based map of the human proteome","author":"Uhl\u00e9n","year":"2024","journal-title":"Hum Protein Atlas"},{"issue":"5","key":"10.1016\/j.gastha.2025.100745_bib41","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.gastha.2025.100745_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.gastha.2025.100745_bib43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.23708","article-title":"Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1","volume":"52","author":"Triantis","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2025.100745_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1150222","article-title":"Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho","volume":"14","author":"Aaldijk","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.gastha.2025.100745_bib45","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","article-title":"Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis","volume":"41","author":"Hendriks","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.gastha.2025.100745_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.24702","article-title":"The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract","volume":"55","author":"Zweers","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gastha.2025.100745_bib47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1665-2681(19)30766-5","article-title":"Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19","volume":"14","author":"Barrera","year":"2015","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2025.100745_bib48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41395-018-0042-7","article-title":"Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial","volume":"113","author":"Oduyebo","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.gastha.2025.100745_bib49","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.gastha.2025.100745_bib50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.gastha.2025.100745_bib51","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.gastha.2025.100745_bib52","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s42255-022-00572-2","article-title":"\u03b2-Klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130","volume":"4","author":"Geng","year":"2022","journal-title":"Nat Metab"},{"issue":"12","key":"10.1016\/j.gastha.2025.100745_bib53","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/cne.24668","article-title":"The central fibroblast growth factor receptor\/beta klotho system: comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform","volume":"527","author":"Hultman","year":"2019","journal-title":"J Comp Neurol"},{"issue":"10","key":"10.1016\/j.gastha.2025.100745_bib54","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Tacer","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"9","key":"10.1016\/j.gastha.2025.100745_bib55","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/en.2012-1193","article-title":"TNF-\u03b1 represses \u03b2-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway","volume":"153","author":"D\u00edaz-Delf\u00edn","year":"2012","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.gastha.2025.100745_bib56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5009\/gnl17443","article-title":"Expression of fibroblast growth factor 21 and \u03b2-klotho regulates hepatic fibrosis through the nuclear factor-\u03baB and c-Jun N-Terminal kinase pathways","volume":"12","author":"Lee","year":"2018","journal-title":"Gut and Liver"},{"issue":"4","key":"10.1016\/j.gastha.2025.100745_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1152\/ajpendo.00356.2015","article-title":"IL-1\u03b2 inhibits \u03b2-Klotho expression and FGF19 signaling in hepatocytes","volume":"310","author":"Zhao","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.gastha.2025.100745_bib58","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40618-023-02273-3","article-title":"Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice","volume":"47","author":"Di Vincenzo","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"10.1016\/j.gastha.2025.100745_bib59","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00535-024-02122-x","article-title":"Effect of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T09:31:38Z","timestamp":1764927098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572325001323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2772572325001323"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100745","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Klotho Protein Expression in Healthy Human Tissues and Liver Biopsies From Patients With MASLD or MASH","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100745"}}